Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Comparison of short-term clinical outcomes between ticagrelor versus clopidogrel in patients with acute myocardial infarction undergoing successful revascularization; from Korea Acute Myocardial Infarction Registry-National Institute of Health

Authors
Park, Keun-HoJeong, Myung HoAhn, YoungkeunAhn, Tae HoonSeung, Ki BaeOh, Dong JooChoi, Dong-JooKim, Hyo-SooGwon, Hyeon CheolSeong, InWhanHwang, Kyung KukChae, Shung ChullKim, Kwon-BaeKim, Young JoCha, Kwang SooOh, Seok KyuChae, Jei Keon
Issue Date
15-7월-2016
Publisher
ELSEVIER IRELAND LTD
Keywords
Myocardial infarction; Ticagrelor; Hemorrhage; Far East
Citation
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.215, pp.193 - 200
Indexed
SCIE
SCOPUS
Journal Title
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume
215
Start Page
193
End Page
200
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/88063
DOI
10.1016/j.ijcard.2016.04.044
ISSN
0167-5273
Abstract
Background: Although ticagrelor has been well-known to improve clinical outcomes in patients with acute myocardial infarction (AMI) without increased bleeding risk, its clinical impacts have not been well established in East Asian patients. Methods: Between November 2011 and June 2015, a total of 8010 patients (1377 patients were prescribed ticagrelor and 6633 patients clopidogrel) undergoing successful revascularization were analyzed from Korea Acute Myocardial Infarction Registry-National Institute of Health. The patients who discontinued or occurred in-hospital switching between two antiplatelet agents were excluded. Results: After propensity score matching (1377 pairs), no difference in the composite of cardiac death, MI, stroke, or target vessel revascularization at 6 months was observed between two groups (4.2% vs. 4.9%, p = 0.499). However, the incidences of in-hospital Thrombolysis In Myocardial Infarction (TIMI) major and minor bleeding were higher in ticagrelor than clopidogrel (2.6% vs. 1.2%, p = 0.008; 3.8% vs. 2.5%, p = 0.051). The in-hospital mortality was higher in patients with than those without TIMI major bleeding (11.3% vs. 0.9%, p < 0.001). In a subgroup analysis, a higher risk for in-hospital TIMI major bleeding with ticagrelor was observed in patients = 75 years or with body weight < 60 kg (odd ratio [OR] = 3.209; 95% confidence interval [CI] = 1.356-7.592) and in those received trans-femoral intervention (OR = 1.996; 95% CI = 1.061-3.754). Conclusions: Our study shows that ticagrelor did not reduce ischemic events yet, however, was associated with increased risk of bleeding complications compared with clopidogrel. Further large-scale, long-term, randomized trials should be required to assess the outcomes of ticagrelor for East Asian patients with AMI. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE